<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21</volume><submitter>Akhavan B</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Since 2022, the global epidemiology of Mpox (MPXV) has transformed, with Clade IIb driving widespread transmission in non-endemic regions and Clade I resurging across Central Africa. Genomic adaptations, such as APOBEC3 mutations, and increasing human-to-human transmission have raised public health alarms. This review synthesizes the latest evidence on Clade I and Clade II MPXV outbreaks from 2022 to 2024, with an emphasis on geographic expansion, demographic disparities, and systemic response gaps.&lt;h4>Methods&lt;/h4>A comprehensive literature search was conducted between September and December 2024 using PubMed, CDC, WHO, and ECDC databases. Studies were included if they reported primary data on Clade I or Clade II MPXV epidemiology. Gray literature, including public healt</pubmed_abstract><journal>One health (Amsterdam, Netherlands)</journal><pagination>101232</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12538092</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>From forest to frontline: A comprehensive review of Mpox's global leap and viral evolution (2022-2024).</pubmed_title><pmcid>PMC12538092</pmcid><pubmed_authors>Alkhouri S</pubmed_authors><pubmed_authors>To W</pubmed_authors><pubmed_authors>Batra K</pubmed_authors><pubmed_authors>Akhavan B</pubmed_authors><pubmed_authors>Ahmed AB</pubmed_authors></additional><is_claimable>false</is_claimable><name>From forest to frontline: A comprehensive review of Mpox's global leap and viral evolution (2022-2024).</name><description>&lt;h4>Background&lt;/h4>Since 2022, the global epidemiology of Mpox (MPXV) has transformed, with Clade IIb driving widespread transmission in non-endemic regions and Clade I resurging across Central Africa. Genomic adaptations, such as APOBEC3 mutations, and increasing human-to-human transmission have raised public health alarms. This review synthesizes the latest evidence on Clade I and Clade II MPXV outbreaks from 2022 to 2024, with an emphasis on geographic expansion, demographic disparities, and systemic response gaps.&lt;h4>Methods&lt;/h4>A comprehensive literature search was conducted between September and December 2024 using PubMed, CDC, WHO, and ECDC databases. Studies were included if they reported primary data on Clade I or Clade II MPXV epidemiology. Gray literature, including public healt</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-04T16:15:07.905Z</modification><creation>2026-05-13T14:24:24.19Z</creation></dates><accession>S-EPMC12538092</accession><cross_references><pubmed>41127628</pubmed><doi>10.1016/j.onehlt.2025.101232</doi></cross_references></HashMap>